ReviewCureus2022
Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment.
Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The effect of caffeine consumption on age-related macular degeneration: a systematic review and meta-analysis.International ophthalmology · 2025Pooled it
- Systematic review on biomarker potential of vitreous microRNA in retinal disease.Frontiers in ophthalmology · 2025Pooled it
- Chronic kidney disease increases the risks of age-related macular degeneration: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Targeted Fluorescence Imaging of Bevacizumab-800CW in Patients with Neovascular Age-Related Macular Degeneration.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- Usability of the SB11 Pre-filled Syringe (PFS) in Patients with Retinal Diseases.Advances in therapy · 2024Trial
- Aptamers in Ocular Disease Therapy and Drug Delivery: Current Progress and Future Opportunities.Current therapeutic research, clinical and experimental · 2026Review
- Pharmacodynamics of Free VEGF After Treatment with the Port Delivery Platform with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.Ophthalmology science · 2026Article
- Association between choroidal structure and retinal fluid location in type 1 neovascular age-related macular degeneration.Eye (London, England) · 2026Article
- Injectable Artificial Photoreceptors: STEM Cell Functional Integration and in vivo Electrophysiological Validation in Retinal Degeneration Models.Small science · 2026Article
- Visual Functioning and Progression from Intermediate Age-Related Macular Degeneration (AMD) to Advanced AMD.Ophthalmic epidemiology · 2026Article
- Faricimab in Treatment-Naïve nAMD: Regional UK Real-World Experience.Advances in therapy · 2026Article
- Cell-type-focused compound screen in human organoids reveals CK1 inhibition protects cone photoreceptors from death.Neuron · 2026Article
- Baseline visual acuity gaps in age-related macular degeneration: AREDS smokers and non-smokers.BMC ophthalmology · 2026Observational
- Impact of a structured patient engagement program on treatment adherence, injection persistence, and visual outcomes in real-world anti-VEGF therapy for neovascular age-related macular degeneration.BMC ophthalmology · 2026Observational
- Real-world treatment patterns and visual outcomes of faricimab in patients with neovascular age-related macular degeneration in the UK at 12 months: the FARWIDE-nAMD study.Eye (London, England) · 2026Observational
- OCT Risk Factors for Progression to Late-Stage Age-Related Macular Degeneration in the Amish Eye Study.Ophthalmology. Retina · 2026Observational
- Beyond Cost: Faricimab as a Driver of Service Efficiency and Quality in Neovascular Age-Related Macular Degeneration Care.Ophthalmology and therapy · 2026Article
- Ergothioneine as a potential protective agent against macular degeneration and other eye disorders.Scientific reports · 2026Article
- Human retinal organoid model of disease-relevant photoreceptor cell death amenable to drug screening.Cell death & disease · 2026Article
- Evaluation of the triglyceride-glucose index, serum inflammatory biomarkers and lipid profile in patients with neovascular age-related macular degeneration.International ophthalmology · 2026Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The greatest global root of irremediable amaurosis in the venerable is age-related macular degeneration (AMD), a complex eye condition. Clinically, AMD is characterized as being in an early stage to late stage and initially affects the macula, which is the center of the retina (advanced AMD). Age-related cellular and metabolic imbalance are made worse by the creation of excessive amounts of free radical species, which causes mitochondrial malfunction. As a result, in AMD-affected eyes, the deprivation of melanocytes, confection, and eventually atrophy within the retinal tissue are caused by the continued proliferation of oxidative stress caused by systemic antioxidant capacity depletion. In the urbanized, industrialized world, age-related macular degeneration (AMD) is one of the major causes of central vision loss in the older age group. Although several causes and mechanisms for the dysfunction and degeneration of the retinal pigment epithelium (RPE) have previously been identified, the condition's symptoms are still not fully understood. Etiopathogenesis is still not entirely understood. As a result, the RPE fails, allowing an accumulation of aberrant misfolded proteins, due to the loss of anatomical control over oppression, altered homeostasis, dysfunctional lipid homeostasis, and failure of mitochondria. Due to the multitude of interconnected processes, numerous complicated therapy combinations will probably be the best option to deliver the best visual outcomes; these combinations will vary depending on the kind and degree of the condition being treated. Undoubtedly, this will lead to the development of customized preventative medications and, hopefully, the revelation of a potential cure. All the mechanisms involved in the etiology of AMD should be continuously probed to create covariates for other contemporaneous or future problems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.